Back to results
CompletedPhase 2

Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients

NCT00432172

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Corporació Sanitaria Parc Taulí

Sabadell, Barcelona, Spain

+11 additional locations

View on ClinicalTrials.gov
Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients — TrialFind